Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
. vivax infection, the species cannot be determined (v) quantification is not possible (vi) operator misunderstanding or misinterpretation of test line patterns may lead to apparent discrepancy between RDT and blood film results (vii) rarely, a prozone effect may occur with HRP2 based RDTs (Luchavez et al , ). Currently available RDTs cannot specifically identify P. knowlesi . HRP2‐based test lines detect only P. falciparum . Plasmodium lactate dehydrogenase (pLDH) and aldolase‐based test lines may (...) detect P. knowlesi as ‘malaria parasites’ but cannot identify the species. A hospital study in Malaysia detected 74% of PCR‐confirmed P. knowlesi using a pan‐pLDH RDT test line and a pan‐aldolase RDT test line detected 23%. The authors commented that neither the pLDH‐ nor aldolase‐based RDT they tested demonstrated sufficiently high overall sensitivity for P. knowlesi (Barber et al , ). The World Health Organization has produced detailed performance assessment of commercially available RDTs (see
for a median of 6 months after discontinuation of therapy (Faoro et al , ). JAK inhibitors JAK inhibitors may have a future role in the management of splenomegaly (see ‘Novel Therapies’ section) and are the only therapies to have been evaluated in the context of randomized clinical trials. Recommendations: medical management of splenomegaly First Line: Hydroxycarbamide (in the absence of cytopenias). Thalidomide and prednisolone (in presence of cytopenias) – consider lenalidomide (if anaemic with platelet (...) count >100 × 10 9 /l). Second Line: Consideration should be given to the use of JAK inhibitors either as part of a clinical trial, or via patient access protocols. These agents are now approved in the USA for first line therapy which is appropriate following approval (Evidence level 1, Grade A). Surgical management The place of splenectomy in the management of myelofibrosis is well established (Barosi et al , ; Tefferi et al , ). Routine splenectomy is inappropriate and the procedure should
was searched using the key words 'nail psoriasis' and 'psoriatic arthritis'. Psoriasis involving the nail matrix shows up as changes such as pitting, Beaulines, leukonychia, red spots in the lunula, or nail plate crumbling. Nail bed psoriasis manifests as onycholysis, oil drops (or salmon patches), dyschromia, splinter hemorrhages, or subungual hyperkeratosis. Nail psoriasis and psoriatic lesions in the gluteal cleft and on the scalp usually accompany PsA, especially in adult men.
morphology, cytogenetics, molecular genetics, and immunologic markers in an attempt to construct a classification that is universally applicable and prognostically valid.[ ] In the older French-American-British (FAB) criteria, the classification of AML is solely based upon morphology as determined by the degree of differentiation along different cell lines and the extent of cell maturation.[ , ] Under the WHO classification, the category “acute myeloid leukemia not otherwise categorized” is morphology (...) With Multilineage Dysplasia In the WHO classification, refractory anemia with excess blasts in transformation (RAEB-t) is no longer considered a distinct clinical entity and is instead included within the broader category “AML with multilineage dysplasia” as one of the following: AML evolving from an MDS. AML following an MDS. AML with multilineage dysplasia is characterized by 20% or more blasts in the blood or bone marrow and dysplasia in two or more myeloid cell lines, generally including megakaryocytes
, a gene involved in purine biosynthesis.[ ] Mutations were observed in 13.0% of a Chinese cohort and 2.7% of a German cohort, and were observed in patients with on-treatment relapses. The PRSP1 mutations observed in relapsed cases induce resistance to thiopurines in leukemia cell lines. CREBBP mutations are also enriched at relapse and appear to be associated with increased resistance to glucocorticoids.[ , ] With increased understanding of the genomics of relapse, it may be possible to tailor upfront
abnormalities in presence of persistent cytopenias of undetermined origin should be considered to support a presumptive diagnosis of MDS when morphological characteristics are not observed. f The diagnostic criteria for childhood MDS (refractory cytopenia of childhood [RCC]-provisional entry) include: 1) persistent cytopenia of 1–3 cell lines with <5% bone marrow blasts, <2% peripheral blood blasts, and no ringed sideroblasts and 2) dysplastic changes in 1–3 lineages should be present. Table 4. Definitions
Idiopathic Sporadic Onychomadesis of Toenails Onychomadesis is a clinical sign of nail plate separation due to transient or permanent arrest of nail matrix activities. Onychomadesis can be considered as a severe form of Beau'sline. This condition usually occurs after trauma, causal diseases, or medications, yet it rarely occurs as an idiopathic condition. We report a case of a 38-year-old Thai female who developed recurrence onychomadesis in several toenails in the absence of predisposing
: Mahidol University Information provided by (Responsible Party): Mahidol University Study Details Study Description Go to Brief Summary: Nail surface abnormalities is any conditions that affect the nail matrix or nail bed which cause nail plates grow defectively. Common nail surface abnormalities are pitting nails, longitudinal ridging, and transverse ridging/Beau'sline. Aging nails usually have nail surface abnormalities as well. Nail gels are artificial nails used widely for aesthetic purposes
Nail findings in hand-foot-and-mouth disease. Hand-foot-and-mouth disease (HFMD) is a common self-limited viral illness seen in the United States and around the world. Its classic features are easily recognizable; however, nail changes are not well known or characterized. This case demonstrates onychomadesis and Beaulines in a child following clinical diagnosis of hand-foot-and-mouth disease. In this setting, nail dystrophies should be reassuring to pediatricians and families.
MDS (refractory cytopenia of childhood [RCC]-provisional entry) include: 1) persistent cytopenia of 1–3 cell lines with <5% bone marrow blasts, <2% peripheral blood blasts, and no ringed sideroblasts and 2) dysplastic changes in 1–3 lineages should be present. MDS with single lineage dysplasia Unilineage dysplasia: ≥10% in one myeloid lineage 1–2 cytopenias b <5% blasts Blasts <1% c <15% ring sideroblasts MDS with ring sideroblasts (MDS-RS) Erythroid dysplasia only <5% blasts No blasts ≥15% ring
) criteria, the classification of AML is solely based upon morphology as determined by the degree of differentiation along different cell lines and the extent of cell maturation.[ , ] Under the WHO classification, the category “acute myeloid leukemia not otherwise categorized” is morphology-based and reflects the FAB classification with a few significant modifications.[ , ] The most significant difference between the WHO and FAB classifications is the WHO recommendation that the requisite blast (...) dysplasia” as one of the following: AML evolving from an MDS. AML following an MDS. AML with multilineage dysplasia is characterized by 20% or more blasts in the blood or bone marrow and dysplasia in two or more myeloid cell lines, generally including megakaryocytes.[ ] To make the diagnosis, dysplasia must be present in 50% or more of the cells of at least two lineages and must be present in a pretreatment bone marrow specimen.[ , ] AML with multilineage dysplasia may occur de novo or following MDS
of heavy users. There are also concerns that a for-profit industry and its lobbyists will fight against regulation and taxation. Thus, serious thought should be given to whether marijuana should be supplied by profit-maximizing firms. Besides home production and cooperatives, other options include limiting the market to nonprofit organizations or “for-benefit corporations,” which typically focus on the triple-bottom line of people, planet, and profits. Jurisdictions could also limit supply to a state (...) in Washington, D.C., and collectives being implemented in Uruguay highlight some of the other non-commercial approaches. While these 10 Ps are not the only choices confronting jurisdictions considering changes in marijuana policy, they cover many of the critical decisions that will determine whether removing prohibition is a good idea. May they serve as fodder for debate and as an outline for jurisdictions seeking guidance if they decide to legalize. Beau Kilmer is the co-director of the RAND Drug Policy
that the increase in marijuana use resulting from legal availability and lower prices will increase dependence and other negative health consequences, such as contributing to a rise in individuals experiencing psychotic symptoms. Opponents also fear that marijuana will be marketed in the same manner as alcohol and that there will be a new industry with lobbyists who would fight against regulation and taxation (or, for that matter, that existing tobacco companies might enter this line of business) The remainder (...) of this commentary is available on . Beau Kilmer is co-director of the RAND Drug Policy Research Center and co-author of " ," (Oxford University Press, 2012). This commentary originally appeared in Britannica Book of the Year on April 21, 2015. Commentary gives RAND researchers a platform to convey insights based on their professional expertise and often on their peer-reviewed research and analysis. Codirector, RAND Drug Policy Research Center; Interim Director, RAND San Francisco Bay Area; Senior Policy
+ / KIT + pluripotent hematopoietic cells in the bone marrow. [ ] The neoplastic clone of mast cells express abnormal cell surface markers CD25 and/or CD2. Mueller et al reported that the adhesion molecule CD44 is expressed in systemic mastocytosis cell lines and correlates with the aggressiveness of the disorder. They found that serum levels of soluble CD44 were higher in advanced systemic mastocytosis compared with indolent systemic mastocytosis or cutaneous mastocytosis, and correlated with overall (...) ] Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood . 2016 May 19. 127 (20):2391-405. . . Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia . 2009 May. 23(5):900-4. . Butterfield JH. Survey of aspirin administration in systemic
survival. Leuk Res . 2017 May. 56:44-51. . [Guideline] NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. National Comprehensive Cancer Network. Available at . Version 5.2017 — October 27, 2017; Accessed: January 16, 2018. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood . 2016 May 19. 127 (20):2391-405. . Roberts KG, Li Y, Payne-Turner D (...) of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica . 2015 May. 100 (5):653-61. . Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood . 1998 Sep 15
Organization classification of myeloid neoplasms and acute leukemia now includes a subtype "Myeloid neoplasms with germ line predisposition". [ ] Thus, to properly classify patients with AML, these genes must be included in nextgen panels. Some hereditary cancer syndromes, such as Li-Fraumeni syndrome, can manifest as leukemia. However, cases of leukemia are less common than the solid tumors that generally characterize these syndromes. Environmental exposures Several studies demonstrate a relationship (...) the and the , as well as and . Previous References Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood . 2016 May 19. 127 (20):2391-405. . . Smith MT, Skibola CF, Allan JM, Morgan GJ. Causal models of leukaemia and lymphoma. IARC Sci Publ . 2004. 373-92. . Ghiaur G, Wroblewski M, Loges S. Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation. Semin Hematol